Wells Fargo & Company Forecasts Strong Price Appreciation for Omnicell (NASDAQ:OMCL) Stock

Omnicell (NASDAQ:OMCL) had its price target boosted by analysts at Wells Fargo & Company from $52.00 to $55.00 in a research report issued on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective would suggest a potential upside of 51.35% from the stock’s current price.

OMCL has been the subject of a number of other research reports. Weiss Ratings lowered shares of Omnicell from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, March 2nd. UBS Group set a $60.00 price objective on shares of Omnicell and gave the company a “buy” rating in a report on Friday, March 13th. Zacks Research upgraded shares of Omnicell from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Bank of America upgraded shares of Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 price objective for the company in a report on Wednesday, February 4th. Finally, Benchmark reissued a “buy” rating on shares of Omnicell in a research report on Friday, March 13th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $59.00.

Omnicell Trading Down 0.8%

OMCL traded down $0.31 on Thursday, reaching $36.34. 26,520 shares of the company traded hands, compared to its average volume of 598,126. Omnicell has a one year low of $22.66 and a one year high of $55.00. The firm has a fifty day simple moving average of $36.81 and a two-hundred day simple moving average of $39.10. The company has a market cap of $1.65 billion, a P/E ratio of 907.98, a price-to-earnings-growth ratio of 1.32 and a beta of 0.85. The company has a quick ratio of 1.22, a current ratio of 1.43 and a debt-to-equity ratio of 0.14.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, February 5th. The company reported $0.40 earnings per share for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.07). Omnicell had a net margin of 0.17% and a return on equity of 3.00%. The company had revenue of $313.98 million for the quarter, compared to the consensus estimate of $313.36 million. During the same quarter in the previous year, the business earned $0.60 EPS. The company’s quarterly revenue was up 2.3% compared to the same quarter last year. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. As a group, equities research analysts expect that Omnicell will post 0.92 earnings per share for the current year.

Insider Buying and Selling

In other Omnicell news, EVP Corey J. Manley sold 7,405 shares of the firm’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $34.69, for a total transaction of $256,879.45. Following the transaction, the executive vice president owned 96,717 shares of the company’s stock, valued at approximately $3,355,112.73. This trade represents a 7.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 2.52% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in OMCL. AQR Capital Management LLC increased its position in Omnicell by 42.1% during the 1st quarter. AQR Capital Management LLC now owns 17,936 shares of the company’s stock valued at $627,000 after purchasing an additional 5,311 shares during the period. Empowered Funds LLC grew its position in shares of Omnicell by 14.3% in the 1st quarter. Empowered Funds LLC now owns 9,953 shares of the company’s stock worth $348,000 after buying an additional 1,243 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Omnicell by 4.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company’s stock worth $4,337,000 after acquiring an additional 4,866 shares in the last quarter. Jane Street Group LLC raised its stake in shares of Omnicell by 201.5% during the 1st quarter. Jane Street Group LLC now owns 163,664 shares of the company’s stock worth $5,722,000 after acquiring an additional 109,382 shares in the last quarter. Finally, Creative Planning lifted its position in Omnicell by 16.7% during the second quarter. Creative Planning now owns 9,390 shares of the company’s stock valued at $276,000 after acquiring an additional 1,347 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.